The Cancer Biology & Therapeutics Program aims to integrate various basic research activities, platform technologies and pre-clinical model systems available within Peter Mac to discover, develop, characterise and refine novel cancer therapeutics for clinical use for solid tumours...

Harnessing the power of the immune system to fight cancer through research into cancer immune surveillance and chemo/immunotherapy, defining key cells and molecules that can elicit an effective response to tumours.

The Computational Biology Program uses mathematics, statistics and computing to generate new discoveries in cancer. We develop new models, algorithms and software tools, and apply these to make sense of cancer data. This includes whole genome, exome, transcriptome and epigenome sequencing data.

The Peter Mac Gastrointestinal Cancer Program provides a focus for clinical, preclinical, and basic science research across all cancers of the gastrointestinal tract (including oesophageal, gastric, colorectal and anal cancers).

The primary focus of the Organogenesis Program is to investigate the process of organ development and how failure of organogenesis contributes to cancer.

The program is interested in understanding the key role played by non-malignant cells within the tumour microenvironment, which includes stromal cells, blood vascular endothelial cells, lymphatic endothelial cells and immune cells.

Cancer is fundamentally a polygenic disorder, imparted by germline and somatic mutations.

Peter Mac is committed to linking patient care with cancer research. Our clinician researchers take their observations from the clinic and plan their research directions with patients in mind.